227 related articles for article (PubMed ID: 28408104)
1. Long-term treatment with ivabradine over 12months in patients with chronic heart failure in clinical practice: Effect on symptoms, quality of life and hospitalizations.
Zugck C; Störk S; Stöckl G;
Int J Cardiol; 2017 Aug; 240():258-264. PubMed ID: 28408104
[TBL] [Abstract][Full Text] [Related]
2. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.
Zugck C; Martinka P; Stöckl G
Adv Ther; 2014 Sep; 31(9):961-74. PubMed ID: 25160945
[TBL] [Abstract][Full Text] [Related]
3. Quality of life improvement in older patients with heart failure initiated on ivabradine: Results from the UK multi-centre LIVE:LIFE prospective cohort study.
Zachariah D; Stevens D; Sidorowicz G; Spooner C; Rowell N; Taylor J; Kay R; Salek MS; Kalra PR;
Int J Cardiol; 2017 Dec; 249():313-318. PubMed ID: 29121732
[TBL] [Abstract][Full Text] [Related]
4. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program.
Lopatin YM; Cowie MR; Grebennikova AA; Sisakian HS; Pagava ZM; Hayrapetyan HG; Abdullaev TA; Voronkov LG; Chesnikova AI; Tseluyko VI; Tarlovskaya EI; Dadashova GM; Berkinbaev SF; Glezer MG; Koziolova NA; Rakisheva AG; Kipiani ZV; Kurlyanskaya AK
Int J Cardiol; 2018 Jun; 260():113-117. PubMed ID: 29622423
[TBL] [Abstract][Full Text] [Related]
5. Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
Sallam M; Al-Saadi T; Alshekaili L; Al-Zakwani I
Curr Vasc Pharmacol; 2016; 14(5):481-486. PubMed ID: 27145825
[TBL] [Abstract][Full Text] [Related]
6. Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine.
Elder DH; Mohan M; Cochrane L; Charles H; Lang CC
Cardiovasc Ther; 2015 Jun; 33(3):104-8. PubMed ID: 25809454
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
[No Abstract] [Full Text] [Related]
8. Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure.
Rohm I; Kretzschmar D; Pistulli R; Franz M; Schulze PC; Stumpf C; Yilmaz A
J Immunol Res; 2016; 2016():6949320. PubMed ID: 27822484
[No Abstract] [Full Text] [Related]
9. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.
Bonnet D; Berger F; Jokinen E; Kantor PF; Daubeney PEF
J Am Coll Cardiol; 2017 Sep; 70(10):1262-1272. PubMed ID: 28859790
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of ivabradine in Chinese patients with chronic heart failure: an observational study.
Zhou J; Xu Y; Zheng Z; Zhang S; Yang J; Zhang Y; Tang B; Han H; Zhang Q; Liu F; Ding W; Qian C; Su G; Liu X; Shen Y; Shi B; Kong X; Ge Z; Zhang P; Guo X; Zhang H; Sun Y; Dong Y; Fu G; Feng L; Ge J;
ESC Heart Fail; 2024 Apr; 11(2):846-858. PubMed ID: 38193606
[TBL] [Abstract][Full Text] [Related]
11. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
Pei H; Miao W; Xie WZ; Wang W; Zhao D; Su GH; Zhao Z
Int Heart J; 2019 Jul; 60(4):899-909. PubMed ID: 31308326
[TBL] [Abstract][Full Text] [Related]
12. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
13. [Ivabradine for Treatment of Heart Failure with Preserved Ejection Fraction].
Babushkina GV; Shaikhlislamova GI
Kardiologiia; 2020 Oct; 60(10):33-37. PubMed ID: 33228503
[TBL] [Abstract][Full Text] [Related]
14. [Comparative Evaluation of -blockers and If-Channel Inhibitor in Patients With Chronic Heart Failure and Preserved Left Ventricular Ejection Fraction].
Kanorsky SG; Borisenko YV
Kardiologiia; 2016 Feb; 56(2):24-29. PubMed ID: 28294745
[TBL] [Abstract][Full Text] [Related]
15. Ivabradine.
Komajda M
Handb Exp Pharmacol; 2017; 243():167-175. PubMed ID: 27752846
[TBL] [Abstract][Full Text] [Related]
16. Ivabradine: Role in the Chronic Heart Failure Armamentarium.
Psotka MA; Teerlink JR
Circulation; 2016 May; 133(21):2066-75. PubMed ID: 27217432
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice.
Perings S; Stöckl G; Kelm M;
Adv Ther; 2016 Sep; 33(9):1550-64. PubMed ID: 27432382
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
[TBL] [Abstract][Full Text] [Related]
19. Heart rate manipulation in dilated cardiomyopathy: Assessing the role of Ivabradine.
Raja DC; Kapoor A; Sinha A; Kashyap S; Khanna R; Kumar S; Garg N; Tewari S; Goel P
Indian Heart J; 2018; 70(2):246-251. PubMed ID: 29716702
[TBL] [Abstract][Full Text] [Related]
20. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
